<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="/pages/css/rss.css" type="text/css"?>
<rss xmlns:ps="http://trailfire.com" version="2.0"><channel><title>"OVP" by ebenson</title><link>http://trailfire.com/ebenson/trails/3917</link><category>ebenson/trails</category><ttl>60</ttl><item><title>Allozyne</title><link>http://trailfire.com/ebenson/marks/4584</link><description><![CDATA[Seattle based spinout from biotech incubator Accelerator Corporation Board: Chad Waite OVP co-invested in a $3.5m round at a $45m premoney valuation Other investors: Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, MPM Capital Summary: Developer of drugs utilizing synthetic amino acids. The company&#39;s technology centers on the modification of expressed proteins through the inclusion of synthetic amino acids in order to develop therapeutic proteins and monoclonal antibodies. The technology is applicable to any number of proteins.]]></description><category>OVP</category><author>ebenson</author><pubDate>Sat, 20 May 2006 08:06:20 -0700</pubDate><guid isPermalink="false">trailfire:markId:4584</guid></item><item><title>Accelerator Corporation</title><link>http://trailfire.com/ebenson/marks/4581</link><description><![CDATA[Seattle based biotech incubation and investment vehicle Board: Chad Waite OVP co-invested in a $21.8m round Co-investors: Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, Institute for Systems Biology, MPM Capital, Versant Ventures Summary: Provider of scientific and technical expertise, support, capital, facilities, and infrastructure. The company provides start-up business management, operational infrastructure, and support for nascent biotechnology companies. The company identifies, evaluates, capitalizes, and develops life science and healthcare innovations, and technologies.]]></description><category>OVP</category><author>ebenson</author><pubDate>Fri, 26 May 2006 15:34:21 -0700</pubDate><guid isPermalink="false">trailfire:markId:4581</guid></item><item><title>Complete Genomics</title><link>http://trailfire.com/ebenson/marks/4588</link><description><![CDATA[San Diego-based DNA sequencing company Board: Chad Waite OVP co-invested with Enterprise Partners on a $6m Series A round in March 2006 Summary: Developer of DNA sequencing methods. The company develops a combination of chemistry and computation that focuses on reducing the cost of DNA sequencing for cancer research, drug development, and diagnostics applications.]]></description><category>OVP</category><author>ebenson</author><pubDate>Fri, 19 May 2006 15:36:03 -0700</pubDate><guid isPermalink="false">trailfire:markId:4588</guid></item><item><title>GenoLogics</title><link>http://trailfire.com/ebenson/marks/4589</link><description><![CDATA[Victoria, B.C.-based bioinformatics software Board: Chad Waite In January 2005, GenoLogics completed a $5m Series A round with OVP and Vancouver, B.C. based Growthworks and Yaletown Venture Partners Summary: provider of an open integrating platform and bioinformatics solutions that help life science and pharmaceutical laboratories, specializing in the field of proteomics and systems biology research, to manage, integrate and analyze enormous volumes of scientific and lab data to advance health science research and drug discovery.]]></description><category>OVP</category><author>ebenson</author><pubDate>Fri, 19 May 2006 15:41:02 -0700</pubDate><guid isPermalink="false">trailfire:markId:4589</guid></item><item><title>Homestead Clinical</title><link>http://trailfire.com/ebenson/marks/4590</link><description><![CDATA[Seattle-based bioinformatics spin out from Accelerator Corporation Board: Chad Waite OVP co-invested with rest of Accelerator Corp VC investors on a $5m Series A round in July 2005; Vulcan Capital is on the board as well. Summary: Developer of technology used to detect diseases and cancers in blood. The company will use logarithms and institute-developed diagnostic technology to analyze blood. The technology is based upon a platform using serum biomarkers.]]></description><category>OVP</category><author>ebenson</author><pubDate>Sat, 20 May 2006 08:12:39 -0700</pubDate><guid isPermalink="false">trailfire:markId:4590</guid></item><item><title>Spaltudaq</title><link>http://trailfire.com/ebenson/marks/4593</link><description><![CDATA[Developer of tumor-specific cancer antibody-based therapeutics Board: Chad Waite $2m Series A seed round at $300k premoney valuation Summary: Developer of tumor-specific cancer antibody-based therapeutics. The company&#39;s technology relies upon the patient’s own immune response, yielding not only a specific tumor-binding antibody, but also a validated, disease-associated tumor target. Its platform will enable sampling and recovery of these tumor-specific antibodies with the goal of fulfilling the unmet medical need of novel, safe treatment options for cancer patients.]]></description><category>OVP</category><author>ebenson</author><pubDate>Sat, 20 May 2006 08:12:42 -0700</pubDate><guid isPermalink="false">trailfire:markId:4593</guid></item></channel></rss>
